Highlights Everest Medicines Limited

Equities

1952

KYG3224E1061

Market Closed - Hong Kong S.E. Other stock markets 04:08:06 2024-04-30 am EDT			5-day change	1st Jan Change
24.45 ^HKD	+2.52%		+4.71%	+16.99%

Apr. 25	Everest Medicines' Loss Widens in 2023	MT
Mar. 28	Everest Medicines Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Everest Medicines' Loss Widens in 2023	Apr. 24	MT
Everest Medicines Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Everest Medicines Terminates Collaboration with Canada’s Providence for mRNA COVID-19 Vaccines	Feb. 18	MT
Everest Foresees Surge in 2023 Revenue	Jan. 21	MT
Everest Medicines Limited Provides Earning Guidance for the Year Ended 31 December 2023	Jan. 21	CI
Everest Medicines Announces New Drug Application Acceptance of Nefecon® in Taiwan for the Treatment of Primary IgA Nephropathy in Adult Patients	Dec. 26	CI
Everest Medicines Announces Investigational New Drug Application Acceptance of Zetomipzomib in China	Dec. 03	CI
Everest Medicines Reaffirms Revenue Guidance for the Year 2023 and 2024	Nov. 27	CI
Calliditas? Partner Everest Medicines Announces China NMPA?s Approval of Nefecon® for the Treatment of Primary IgA Nephropathy	Nov. 24	CI
Shortened Post-Thanksgiving Session Keeps Exchange-Traded Funds, Equity Futures Muted Pre-Bell Friday	Nov. 24	MT
Calliditas Therapeutics' Partner Secures Approval for Immunoglobulin Nephropathy Treatment in China	Nov. 24	MT
Everest Medicines Announces China NMPA's Approval of Nefecon for the Treatment of Primary IgA Nephropathy	Nov. 24	CI
Chinese Regulator Approves Everest's NDA for Nephropathy Drug	Nov. 24	MT
National Medical Products Administration Approves the New Drug Application for Nefecon for the Treatment of Primary Immunoglobulin A Nephropathy in Adults At Risk of Disease Progress in China	Nov. 23	CI
Everest Medicines Announces New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy	23-10-27	CI
Everest Medicines Limited Announces Approval of XERAVA® in Taiwan for the Treatment of Complicated Intra-Abdominal Infections in Adult Patients	23-09-27	CI
Kezar Life Sciences Signs License Agreement With Everest Medicines to Develop, Market Zetomipzomib in Asia	23-09-21	MT
Everest Medicines Signs License Deal with Kezar for Anti-Autoimmune Disease Medication	23-09-20	MT
Everest Medicines Enters into Collaboration and License Agreement with Kear Life Sciences to Develop and Commercialize Zetomipzomib in Greater China and Other Asian Markets	23-09-20	CI
Everest Medicines Announces New Drug Application Acceptance by the Pharmaceutical Administration Bureau of Macao for Nefecon(R) for the Treatment of Primary IgA Nephropathy	23-08-24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Everest Medicines Limited

Equities

1952

KYG3224E1061

Highlights

Filters